PXD063643 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Response Marker Enrichment Analysis informs the impact of pharmacological and genetic perturbagens on cancer cells |
| Description | The project focuses on the development and validation of our novel enrichment technique, Response Marker Enrichment Analysis (ReMEA). As part of this validation, we present two datasets consisting of MS/MS analysis of drug treated acute myeloid leukaemia (AML) cell lines. These are as follows: Firstly, we present a total proteomics dataset, whereby the HEL and P31-Fuj cell lines were treated with lysine-specific demethylase 1 (LSD1) inhibitors for 5-days. Here, cells were exposed to two 1µM treatments of either GSK2879552 or iadademstat. This data was then analysed to infer PI3Ki sensitivity as described in the publication. Secondly, we present a phosphoproteomics dataset, consisting of chemotherapy treated cell lines. The cell lines used were the P31-Fuj, MV4-11 and HL-60 cell lines. The chemotherapy treatments consisted of cytarabine, daunorubicin and a combination of the two for either 2, 6, or 24 hours. Cytarabine was used at 2µM, daunorubicin 1µM and co-treatment doses were also 2µM and 1µM for cytarabine and daunorubicin, respectively. This data was then analysed and used to construct our compound activity marker signatures, with which we stratify AML patients using published phosphoproteomics data (as described in the publication). |
| HostingRepository | PRIDE |
| AnnounceDate | 2026-08-20 |
| AnnouncementXML | Submission_2026-08-19_22:37:27.602.xml |
| DigitalObjectIdentifier | https://doi.org/10.6019/PXD063643 |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Supported dataset by repository |
| PrimarySubmitter | Luke Higgins |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606; |
| ModificationList | phosphorylated residue; monohydroxylated residue; iodoacetamide derivatized residue |
| Instrument | Q Exactive |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
|---|
| 0 | 2025-05-06 06:22:30 | ID requested | |
| ⏵ 1 | 2026-08-19 22:37:28 | announced | |
Publication List
Keyword List
| submitter keyword: AML, enrichment analysis, cancer, leukemia, drug treatment proteomics, phosphoproteomics, LC-MS/MS |
Contact List
| Professor Pedro R Cutillas |
|---|
| contact affiliation | Centre for Cancer Evolution Barts Cancer Institute Queen Mary University of London John Vane Science Centre Charterhouse square London EC1M 6BQ |
| contact email | p.cutillas@qmul.ac.uk |
| lab head | |
| Luke Higgins |
|---|
| contact affiliation | Barts Cancer Institute, Queen Mary University of London |
| contact email | l.higgins@qmul.ac.uk |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063643 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD063643
- Label: PRIDE project
- Name: Response Marker Enrichment Analysis informs the impact of pharmacological and genetic perturbagens on cancer cells
